Taysha Gene Therapies (TSHA) Stock Forecast & Price Target

$1.85 0.00 (0.00%)

(As of 12/20/2024 05:45 PM ET)

Taysha Gene Therapies - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 8 Analyst Ratings

Sell
0

Hold
0

Buy
8

Based on 8 Wall Street analysts who have issued ratings for Taysha Gene Therapies in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for TSHA.

Consensus Price Target

$6.63
258.11% Upside

According to the 8 analysts' twelve-month price targets for Taysha Gene Therapies, the average price target is $6.63. The highest price target for TSHA is $8.00, while the lowest price target for TSHA is $5.00. The average price target represents a forecasted upside of 258.11% from the current price of $1.85.

Get the Latest News and Ratings for TSHA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Taysha Gene Therapies and its competitors.

TSHA Analyst Ratings Over Time

Type	Current Forecast 12/23/23 to 12/22/24	1 Month Ago 11/23/23 to 11/22/24	3 Months Ago 9/24/23 to 9/23/24	1 Year Ago 12/23/22 to 12/23/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$6.63	$6.63	$6.38	$5.89
Forecasted Upside	258.11% Upside	168.22% Upside	214.04% Upside	261.28% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Rare "crisis signal" triggers for third time in U.S. market (Ad)

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details.

TSHA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TSHA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Taysha Gene Therapies Stock vs. The Competition

Type	Taysha Gene Therapies	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	258.11% Upside	25,828.18% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent TSHA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Canaccord Genuity Group 1 of 5 stars		Boost Target	Buy ➝ Buy	$6.00 ➝ $8.00	+252.42%
11/14/2024	Chardan Capital 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00	+208.37%
11/12/2024	JMP Securities 2 of 5 stars		Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00	+140.38%
11/12/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$7.00 ➝ $7.00	+329.45%
11/12/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00	+268.10%
7/1/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$9.00 ➝ $7.00	+212.50%
This is the worst sign for the U.S. stock market in 50 years (Ad) The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025.
6/27/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00	+145.10%
5/14/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Buy	$2.00 ➝ $8.00	+233.33%
9/20/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$6.00 ➝ $5.00	+62.87%
8/15/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$6.00 ➝ $8.00	+275.59%
2/2/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/27/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Equal Weight	$23.00 ➝ $3.00	+62.16%
1/4/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$14.00 ➝ $10.00	+354.54%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:49 PM ET.

TSHA Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Taysha Gene Therapies is $6.63, with a high forecast of $8.00 and a low forecast of $5.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares.
: According to analysts, Taysha Gene Therapies's stock has a predicted upside of 258.11% based on their 12-month stock forecasts.
: Taysha Gene Therapies has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, Chardan Capital, JMP Securities, and Needham & Company LLC in the past 90 days.
: Analysts like Taysha Gene Therapies more than other "medical" companies. The consensus rating for Taysha Gene Therapies is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TSHA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Rare "crisis signal" triggers for third time in U.S. market (Ad)

Click here for all the details.

This page (NASDAQ:TSHA) was last updated on 12/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Stock Forecast & Price Target